{"created":"2023-06-19T10:30:05.041714+00:00","id":2175,"links":{},"metadata":{"_buckets":{"deposit":"dbaf6439-cf08-412c-9521-cf17a7a769cf"},"_deposit":{"created_by":31,"id":"2175","owners":[31],"pid":{"revision_id":0,"type":"depid","value":"2175"},"status":"published"},"_oai":{"id":"oai:kwmed.repo.nii.ac.jp:00002175","sets":["1709617079800:35:686"]},"author_link":["109751","109752","109753","109754","109755","109756","109757","109758","109759","109760","109761","109762"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"87","bibliographicPageStart":"81","bibliographicVolumeNumber":"45","bibliographic_titles":[{"bibliographic_title":"川崎医学会誌","bibliographic_titleLang":"ja"},{"bibliographic_title":"Kawasaki medical journal","bibliographic_titleLang":"en"}]}]},"item_10001_description_33":{"attribute_name":"記事種別(日)","attribute_value_mlt":[{"subitem_description":"症例報告","subitem_description_language":"ja","subitem_description_type":"Other"}]},"item_10001_description_34":{"attribute_name":"記事種別(英)","attribute_value_mlt":[{"subitem_description":"Case Report","subitem_description_language":"en","subitem_description_type":"Other"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"川崎医学会","subitem_publisher_language":"ja"}]},"item_10001_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.11482/KMJ-J201945081","subitem_relation_type_select":"DOI"}}]},"item_10001_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://igakkai.kms-igakkai.com/wp/wp-content/uploads/2019/KMJ-J201945081.pdf","subitem_relation_type_select":"URI"}}]},"item_10001_relation_35":{"attribute_name":"医中誌ID","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"2020200380","subitem_relation_type_select":"ICHUSHI"}}]},"item_10001_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN00045593","subitem_source_identifier_type":"NCID"},{"subitem_source_identifier":"AN12940574","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0386-5924","subitem_source_identifier_type":"PISSN"},{"subitem_source_identifier":"2758-089X","subitem_source_identifier_type":"EISSN"}]},"item_10001_text_31":{"attribute_name":"著者所属(日)","attribute_value_mlt":[{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学血液内科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学血液内科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学血液内科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学血液内科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学血液内科学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学血液内科学"}]},"item_10001_text_32":{"attribute_name":"著者所属(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Department of Hematology, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Hematology, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Hematology, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Hematology, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Hematology, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Hematology, Kawasaki Medical School"}]},"item_10001_textarea_5":{"attribute_name":"抄録(英)","attribute_value_mlt":[{"subitem_textarea_language":"en","subitem_textarea_value":"　Ixazomib is an oral proteasome inhibitor that is useful for the treatment of recurrent refractory cases, particularly when a non-injection combination drug therapy is chosen for the patient. Here, we report a case of cardiac amyloidosis treated with ixazomib in a patient with multiple myeloma. The patient was a 50-year-old woman hospitalized in the cardiovascular medicine department of our hospital in October 20XX for close examination of cardiac failure. On the basis of the test findings, sick sinus syndrome (type 3) and cardiac amyloidosis were diagnosed. A heart pacemaker transplantation was performed for the sick sinus syndrome (type 3), and additional tests indicated M-protein expression; thus, the patient was referred to our department. A bone marrow test revealed increased plasma cells, which led to the diagnosis of immunoglobulin light chain amyloidosis (heart and digestive tract) secondary to multiple myeloma (IgG‐λ with BJP). Treatment was initiated in December 20XX. During the first course of VRD treatment, multiple non-pacemaker waveform arrhythmias and congestive heart failure occurred. Left total hemiplegia due to cardioembolic stroke occurred. We judged it difficult to continue the VRD treatment, so we switched the treatment to concomitant elotuzumab and RD therapy. After 2 courses, the patient became PD. With a decrease in ADL due to the onset of cerebral infarction and considering the possible need for institutionalization, ixazomib combined with RD therapy was initiated as treatment to reduce the frequency of outpatient visits. The treatment efficacy and tolerance were good, the M-protein expression level decreased gradually. Her progress was uneventful with no worsening of cardiac failure. Cardiac amyloidosis secondary to multiple myeloma is commonly associated with treatment-related lifethreatening arrhythmias and cardiac failure. Treatment with the proteasome inhibitor bortezomib is associated with the onset of arrhythmias and cardiac failure. However, treatment with the oral proteasome inhibitor ixazomib can be continued without onset of arrhythmia and cardiac failure. "}]},"item_10001_textarea_6":{"attribute_name":"抄録(日)","attribute_value_mlt":[{"subitem_textarea_language":"ja","subitem_textarea_value":"　Ixazomib は，経口のプロテアソーム阻害薬であり，特に非注射薬の組み合わせが選択される多発性骨髄腫患者の再発難治例にとって有用な治療薬である．今回，我々はIxazomib が奏効している心アミロイドーシス合併多発性骨髄腫を経験したため報告する．症例は50歳代女性で，20XX 年10月心不全精査のため当院循環器内科入院となり，精査にて洞不全症候群（type3），心アミロイドーシスと診断された．洞不全症候群（type3）に対して心臓ペースメーカー移植術が施行され，血液検査にてM 蛋白を認めたため当科紹介となった．骨髄検査では形質細胞の増加を認め，AL アミロイドーシス（心臓，消化管）合併多発性骨髄腫（IgG‐λ with BJP）と診断した．20XX 年12月から治療を開始．VRD 療法を１コース施行中に，ペースメーカー波形ではない不整脈が多発し，うっ血性心不全の併発や，心源性脳梗塞による左完全片麻痺を発症した．VRD 療法は継続困難と判断し，elotuzumab 併用RD 療法に変更し治療を施行した．２コースでPD となったため，脳梗塞の発症によるADL の低下があることから，施設入所をふまえて外来通院頻度が少ない治療法として，Ixazomib 併用RD 療法を選択し治療を開始した．治療効果および忍容性は良好で，M 蛋白の順調な低下を認め，心不全の増悪なく経過している．心アミロイドーシス合併多発性骨髄腫は，治療に伴い致死性不整脈や心不全を併発することが多い．プロテアソーム阻害剤であるbortezomib 投与にて，不整脈や心不全の併発症状が出現していたが，経口プロテアソーム阻害剤であるixazomib の投与では，不整脈や心不全を併発させることなく，治療が継続し得た．"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"林, 成樹","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"佐野, 史典","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"安井, 晴之進","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"廣瀬, 匡","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"近藤, 英生","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"和田, 秀穂","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"HAYASHI, Shigeki","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"SANO, Fuminori","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"YASUI, Harunoshin","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"HIROSE, Tadashi","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"KONDO, Eisei","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"WADA, Hideho","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-04-01"}],"displaytype":"detail","filename":"KMJ-J201945081.pdf","filesize":[{"value":"3.4 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"PDF","objectType":"fulltext","url":"https://kwmed.repo.nii.ac.jp/record/2175/files/KMJ-J201945081.pdf"},"version_id":"a26c2419-5ced-4acf-9894-72f9dc9786e0"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"イキサゾミブ","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"心アミロイドーシス","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"多発性骨髄腫","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"Ixazomib","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Cardiac amyloidosis","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Multiple myeloma","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Ixazomib が奏効している心アミロイドーシス合併多発性骨髄腫","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Ixazomib が奏効している心アミロイドーシス合併多発性骨髄腫","subitem_title_language":"ja"},{"subitem_title":"Multiple myeloma-associated cardiac amyloidosis in a patient treated with ixazomib.","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"31","path":["686"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2020-04-01"},"publish_date":"2020-04-01","publish_status":"0","recid":"2175","relation_version_is_last":true,"title":["Ixazomib が奏効している心アミロイドーシス合併多発性骨髄腫"],"weko_creator_id":"31","weko_shared_id":-1},"updated":"2024-04-19T04:11:09.607951+00:00"}